A Review of Human Papillomavirus Vaccination and Associated Ethical Concerns

키워드

참고문헌 (35)

1. Human papillomavirus vaccination, "Committee Opinion No. 704. American College of Obstetricians and Gynecologists", Obstet Gynecol, 129, pp.e173~e178 (2017)
2. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
3. Beavis AL, "Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States", Cancer, 123, pp.1044~1050 (2017)
4. Petrosky E, "Use of 9-valent human papillomavirus(HPV)vaccine : updated HPV vaccination recommendations of the advisory committee on immunization practices", MMWR Morb Mortal Wkly Rep, 64, pp.300~304 (2015)
5. Tomljenovic L, "Too fast or not too fast : the FDA's approval of Merck's HPV vaccine Gardasil", J Law Med Ethics, 40, pp.673~681 (2012)
6. Ikeda S, "HPV vaccination in Japan : what is happening in Japan?", Expert Rev Vaccines, 18, pp.323~325 (2019)
7. Hanley SJ, "HPV vaccination crisis in Japan", Lancet, 385, pp.2571~ (2015)
8. Arana JE, "Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System(VAERS), 2009-2015", Vaccine, 36, pp.1781~1788 (2018)
9. Simms KT, "Impact of HPV vaccine hesitancy on cervical cancer in Japan : a modelling study", Lancet Public Health, 5, pp.e223~e234 (2020)
10. Hansen PR, "Resilience of HPV vaccine uptake in Denmark : decline and recovery", Vaccine, 38, pp.1842~1848 (2020)
11. Klein NP, "Safety of quadrivalent human papillomavirus vaccine administered routinely to females", Arch Pediatr Adolesc Med, 166, pp.1140~1148 (2012)
12. Moreira ED Jr, "Safety profile of the 9-valent HPV vaccine : a combined analysis of 7 phase III clinical trials", Pediatrics, 138, pp.e20154387~ (2016)
13. Chandler RE, "Safety concerns with HPV vaccines continue to linger : are current vaccine pharmacovigilance practices sufficient?", Drug Saf, 40, pp.1167~1170 (2017)
14. Yaju Y, "Safety concerns with human papilloma virus immunization in Japan : analysis and evaluation of Nagoya City's surveillance data for adverse events", Jpn J Nurs Sci, 16, pp.433~449 (2019)
15. Shimabukuro TT, "Safety of the 9-valent human papillomavirus vaccine", Pediatrics, 144, pp.e20191791~ (2019)
16. Phillips A, "Safety of human papillomavirus vaccines : an updated review", Drug Saf, 41, pp.329~346 (2018)
17. Mikamo H, "Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men : a randomized, Phase 3, placebo-controlled study", Vaccine, 37, pp.1651~1658 (2019)
18. Wheeler CM, "Efficacy, safety, and immunogenicity of the human papillomavirus 16", 18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study, 2016, pp.16, 1154~1168
19. Schwarz TF, "A ten-year study of immunogenicity and safety of the AS04-HPV-16", 18 vaccine in adolescent girls aged 10-14 years, 2019, pp.15, 1970~1979
20. "Assessment Report: Review under Article 20 of Regulation (EC) No 726/2004. Human papillomavirus (HPV) vaccines"[URL]
21. "Safety update of HPV vaccines"[URL]
22. Bosch FX, "The causal relation between human papillomavirus and cervical cancer", J Clin Pathol, 55, pp.244~265 (2002)
23. Markowitz LE, "Ten years of human papillomavirus vaccination in the United States", Acad Pediatr, 18(Suppl 2), pp.S3~S10 (2018)
24. Apter D, "Efficacy of human papillomavirus 16 and 18(HPV-16", 18)AS04-adjuvanted vaccine against cervical infection and precancer in young women : final event-driven analysis of the randomized, double-blind PATRICIA trial, 2015, pp.22, 361~373
25. Bergman H, "Comparison of different human papillomavirus(HPV)vaccine types and dose schedules for prevention of HPV-related disease in females and males", Cochrane Database Syst Rev, 2019, pp.CD013479~ (2019)
26. Huh WK, "Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years : a randomised, double-blind trial", Lancet, 390, pp.2143~2159 (2017)
27. Agrawal S, "Who calls the shots? The ethics of adolescentself-consent for HPV vaccination", J Med Ethics, 44, pp.531~535 (2018)
28. Bryan JT, "Developing an HPV vaccine to prevent cervical cancer and genital warts", Vaccine, 25, pp.3001~3006 (2007)
29. Smith JS, "Age-specific prevalence of human papillomavirus infection in males : a global review", J Adolesc Health, 48, pp.540~552 (2011)
30. Kim JJ, "Health and economic implications of HPV vaccination in the United States", N Engl J Med, 359, pp.821~832 (2008)
31. Dunne EF, "CDC grand rounds : reducing the burden of HPV-associated cancer and disease", MMWR Morb Mortal Wkly Rep, 63, pp.69~72 (2014)
32. Walker TY, "National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2018", MMWR Morb Mortal Wkly Rep, 68, pp.718~723 (2019)
33. Holman DM, "Barriers to human papillomavirus vaccination among US adolescents : a systematic review of the literature", JAMA Pediatr, 168, pp.76~82 (2014)
34. Manhart LE, "Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? a meta-analysis", Sex Transm Dis, 29, pp.725~735 (2002)
35. Wang J, "Mode of HPV vaccination delivery and equity in vaccine uptake : A nationwide cohort study", Prev Med, 120, pp.26~33 (2019)

관련 논문AI추천